These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 15460522)

  • 1. Can modulation of viral fitness represent a target for anti-HIV-1 strategies?
    Clementi M
    New Microbiol; 2004 Jul; 27(3):207-14. PubMed ID: 15460522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intra-host evolution of human immunodeficiency virus type 1 and viral fitness.
    Clementi M; Canducci F; Bagnarelli P; Menzo S
    New Microbiol; 2004 Apr; 27(2 Suppl 1):41-4. PubMed ID: 15646063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: a view from the clinic and ex vivo.
    Martinez-Picado J; Martínez MA
    Virus Res; 2008 Jun; 134(1-2):104-23. PubMed ID: 18289713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Viral phenotype and fitness.
    Andreoni M
    New Microbiol; 2004 Apr; 27(2 Suppl 1):71-6. PubMed ID: 15646067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy.
    Nicastri E; Sarmati L; d'Ettorre G; Palmisano L; Parisi SG; Uccella I; Rianda A; Concia E; Vullo V; Vella S; Andreoni M
    J Med Virol; 2003 Jan; 69(1):1-6. PubMed ID: 12436471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human immunodeficiency virus type 1 fitness and tropism: concept, quantification, and clinical relevance.
    Clementi M; Lazzarin A
    Clin Microbiol Infect; 2010 Oct; 16(10):1532-8. PubMed ID: 20678176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The HIV-1 integrase genotype strongly predicts raltegravir susceptibility but not viral fitness of primary virus isolates.
    Buzón MJ; Dalmau J; Puertas MC; Puig J; Clotet B; Martinez-Picado J
    AIDS; 2010 Jan; 24(1):17-25. PubMed ID: 19770695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perspectives and opportunities for novel antiviral treatments targeting virus fitness.
    Clementi M
    Clin Microbiol Infect; 2008 Jul; 14(7):629-31. PubMed ID: 18190573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical significance of viral fitness.
    Geretti AM
    J HIV Ther; 2005 Mar; 10(1):6-10. PubMed ID: 15951728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.
    Ambrose Z; Boltz V; Palmer S; Coffin JM; Hughes SH; Kewalramani VN
    J Virol; 2004 Dec; 78(24):13553-61. PubMed ID: 15564466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo dynamics of the K103N mutation following the withdrawal of non-nucleoside reverse transcriptase inhibitors in Human Immunodeficiency Virus-infected patients.
    Gianotti N; Galli L; Boeri E; Maillard M; Serra G; Ratti D; Gallotta G; Vacchini D; Tremolada Y; Lazzarin A; Clementi M; Castagna A
    New Microbiol; 2005 Oct; 28(4):319-26. PubMed ID: 16386016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo emergence of drug-resistant mutations at less than 50 HIV-1 RNA copies/mL that are maintained at viral rebound in longitudinal plasma samples from human immunodeficiency virus type-1-infected patients on highly active antiretroviral therapy.
    Elbeik T; Hoo BS; Campodonico ME; Dileanis J; Fay FF; Bortolozzi RL; Benetti MS; Fay OH; Marlowe N; Petrauskene O; Chernoff D; Smith L; Ng VL
    J Hum Virol; 2001; 4(6):317-28. PubMed ID: 12082398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid selection of drug-resistant HIV-1 during the first months of suppressive ART in treatment-naive patients.
    Metzner KJ; Allers K; Rauch P; Harrer T
    AIDS; 2007 Mar; 21(6):703-11. PubMed ID: 17413691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale for maintenance of the M184v resistance mutation in human immunodeficiency virus type 1 reverse transcriptase in treatment experienced patients.
    Turner D; Brenner BG; Routy JP; Petrella M; Wainberg MA
    New Microbiol; 2004 Apr; 27(2 Suppl 1):31-9. PubMed ID: 15646062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Processivity and drug-dependence of HIV-1 protease: determinants of viral fitness in variants resistant to protease inhibitors.
    Menzo S; Monachetti A; Balotta C; Corvasce S; Rusconi S; Paolucci S; Baldanti F; Bagnarelli P; Clementi M
    AIDS; 2003 Mar; 17(5):663-71. PubMed ID: 12646788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolutionary pathways of transmitted drug-resistant HIV-1.
    Pingen M; Nijhuis M; de Bruijn JA; Boucher CA; Wensing AM
    J Antimicrob Chemother; 2011 Jul; 66(7):1467-80. PubMed ID: 21502281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV type-1 genotypic resistance profiles in vertically infected patients from Argentina reveal an association between K103N+L100I and L74V mutations.
    Aulicino PC; Rocco CA; Mecikovsky D; Bologna R; Mangano A; Sen L
    Antivir Ther; 2010; 15(4):641-50. PubMed ID: 20587857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The host environment drives HIV-1 fitness.
    van Opijnen T; Berkhout B
    Rev Med Virol; 2005; 15(4):219-33. PubMed ID: 15942979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minority report: hidden memory genomes in HIV-1 quasispecies and possible clinical implications.
    Briones C; Domingo E
    AIDS Rev; 2008; 10(2):93-109. PubMed ID: 18615120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.